The global value of pharmaceutical counterfeiting is $200B annually. More staggering is the forecasted value of the grey market will reach almost $3 trillion by 2022. The economic impact is alarming, but it’s not the only threat. When fake or diverted products enter the market, patient safety is jeopardized, people lose confidence in the medicines they trust, and company revenues suffer. Regulations help, but the long and winding road of serialization has ended and most executives now realize that it doesn’t solve the escalating problems.